Revelation Biosciences Inc.
REVB
Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury ( AKI ) and GEM-CKD as a treatment for chronic kidney disease ( CKD ).
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$12M
▲ +40.7% YoY
Op. Margin
–
ROIC
-95.17%
▲ +10.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▲ +54.9% YoY
Op. Cash Flow (TTM)
-$10M
▲ +54.9% YoY
Net Debt
-$8M
Net Cash Position
Cash & Equiv.
$9M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with REVB
Revelation Biosciences (REVB) in two numbers
Questions about Revelation Biosciences
Is Revelation Biosciences (REVB) overvalued?
Revelation Biosciences trades at 0.02 times earnings. Intrinsiqq's fair value calculator has no opening value for REVB, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Does Revelation Biosciences (REVB) pay a dividend?
No. Revelation Biosciences (REVB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 2 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in REVB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing REVB
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.